Developments and improvements in the manufacturing of human therapeutics with mammalian cell cultures

Trends in Biotechnology

Volumn 18, Issue 4, 2000, Pages 173-180

  Hesse, Friedemann ^a   Wagner, Roland ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DRUG; POLOXAMER; RECOMBINANT GROWTH FACTOR; TRASTUZUMAB;

ADAPTATION; ANIMAL CELL; BIOTECHNOLOGY; CELL CULTURE; CONTAMINATION; CULTURE MEDIUM; DOCUMENTATION; DRUG MANUFACTURE; GOOD MANUFACTURING PRACTICE; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SAFETY; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL SPECIMEN BANKS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CULTURE MEDIA; DRUG INDUSTRY; GUIDELINES; HUMANS; MAMMALS; RECOMBINANT PROTEINS; RISK ASSESSMENT;

MAMMALIA;

EID: 0034176711     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(99)01420-1     Document Type: Review

References (50)

1. Brenner, T.L. and Adams, V.R. (1999) First MAb approved for treatment of metastatic breast cancer. J. Am. Pharm. Assoc. Wash. 39, 236-238
2. Baselga, J. et al. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825-2831
3. Garnick, R.L. (1998) Raw materials as a source of contamination in large-scale cell culture. Dev. Biol. Stand. 93, 21-29
4. Lubiniecki, A.S. and Shadle, P.J. (1997) Raw material considerations. Dev. Biol. Stand. 91, 65-72
5. Asher, D.M. (1999) Bovine sera used in the manufacture of biologicals: current concerns and policies of the US Food and Drug Administration regarding the transmissible spongiform encephalopies. Dev. Biol. Stand. 99, 41-44
6. Shailer, C. and Corrin, K. (1999) Serum supply: policies and controls operating in New Zealand. Dev. Biol. Stand. 99, 71-77
7. Webber, G. (1995) Cleaning up in the antipodes. Biotechnology 13, 337
8. Enders, J.F. et al. (1949) Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109, 85-87
9. Lubiniecki, A.S. (1987) Safety considerations for cell culture-derived biologicals. In: Large Scale Cell Culture Technology (Lydersen, B.K., ed.), pp. 231-247, Hanser
10. Hilleman, M.R. (1979) Line cell saga - an argument in favor of production of biologicals in cancer cells. Adv. Exp. Med. Biol. 118, 47-58
11. Hayflick, L. and Moorhead, P.S. (1961) The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585-621
12. Petricciani, J.C. and Martin, D.P. (1974) Use of nonhuman-primates for assaying tumorigenicity of viral-vaccine cell substrates. Transplant. Proc. 6, 189-192
13. Jacobs, J.P. (1976) Status ofhuman diploid cell strain MRC-5 as an approved substrate for production of viral vaccines. J. Biol. Standard 4, 97-99
14. Hayflick, L. (1984) The coming of age of WI-38. Adv. Cell Culture 3, 303-316
15. Plotkin, S.A. et al. (1965) Studies of immunization with living rubella virus: trials with children with a strain cultured from an aborted fetus. Am. J. Dis. Child. 110, 381-389
16. Plotkin, S.A. et al. (1969) Attenuation of RA27/3 rubella virus in WI-38 human diploid cells. Am. J. Dis. Child. 118, 178-185
17. Plotkin, S.A. et al. (1969) Serially cultured animal cells for preparation of viral vaccines. Science 165, 1278-1282
18. Bouchard, L. et al. (1984) Tumorigenic activity of polyoma-virus and SV40 DNAs in newborn rodents. Virology 135, 53-64
19. Chen, P.L. et al. (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science 250, 1576-1580
20. Monier, R. (1990) Oncogenes and anti-oncogenes in tumorigenesis. Reprod. Nutr. Dev. 30, 445-454
21. Sonenberg, N. (1993) Translation factors as effectors of cell growth and tumorigenesis. Curr. Opin. Cell Biol. 5, 955-960
22. Montagnon, B.J. et al. (1981) The large-scale cultivation of Vero cells in microcarrier-culture for virus-vaccine production: preliminary results for killed poliovirus-vaccine. Dev. Biol. Stand. 47, 55-64
23. Grossbard, E.B. (1987) Recombinant tissue plasminogen activator: a brief review. Pharm. Res. 4, 375-378
24. Egrie, J. (1990) The cloning and production of recombinant human erythropoietin. Pharmacotherapy 10, 3S-8S
25. Schultz, W.B. (1998) International conference on harmonization; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Fed. Regist. Vol. 63, No. 182, 50244-50249
26. Hayflick, L. et al. (1986) History of the acceptance of human diploid cell strains as substrates for human virus vaccine manufacture. Dev. Biol. Stand. 68, 9-17
27. Akers, J. et al. (1994) Biotechnology product validation, part 1: identifying the pitfalls. BioPharm 7, 40-43
28. Wiebe, M.E. and May, L.H. (1990) Cell banking. Bioprocess Technol. 10, 147-160
29. Facklam, T.J. and Geyer, S. (1991) The preparation and validation of stock cultures of mammalian cells. Bioprocess Technol. 13, 54-85
30. Hewlett, G. (1991) Strategies for optimising serum-free media. Cytotechnology 5, 3-14
31. Chang, T.H. et al. (1980) Production of monoclonal antibodies in serum-free medium. J. Immunol. Methods 39, 369-375
32. Murakami, H. et al. (1982) Growth of hybridoma cells in serum-free medium - ethanolamine is an essential component. Proc. Nat. Acad. Sci. U. S. A. 79, 1158-1162
33. Jäger, V. et al. (1988) Serum-free growth medium for the cultivation of a wide spectrum of mammalian cells in stirred bioreactors. Cytotechnology 1, 319-329
34. Merten, O-W. (1999) Safety issues of animal products used in serum-free media. Dev. Biol. Stand. 99, 167-180
35. Eto, N. et al. (1991) Development of a protein-free medium with ferric citrate substituting transferrin for the cultivation of mouse-mouse hybridomas. Agric. Biol. Chem. 55, 863-865
36. Radlett, P.J. et al. (1971) Improvements in growth of BHK-21 cells in submerged culture. Appl. Microbiol. 22, 534-537
37. Mizrahi, A. (1984) Oxygen in human-lymphoblastoid cell-line cultures and effect of polymers in agitated and aerated cultures. Dev. Biol. Stand. 55, 93-102
38. Scharfenberg, K. and Wagner, R. (1995) A reliable strategy for the achievement of cell lines growing in protein-free medium. In: Animal Cell Technology: Developments towards the 21st Century (Beuvery, E.C. et al., eds), pp. 619-623, Kluwer Academic Publishers
39. Mather, J.P. (1998) Making informed choices: medium, serum, and serum-free medium. Methods Cell Biol. 57, 19-30
40. Berthold, W. and Walter, J. (1994) Protein purification: aspects of processes for pharmaceutical products. Biologicals 22, 135-150
41. Leser, E.W. and Asenjo, J.A. (1992) Rational design of purification processes for recombinant proteins. J. Chromatogr. 584, 43-57
42. Walter, J. and Allgaier, H. (1997) Validation of downstream processes. In: Mammalian Cell Biotechnology in Protein Production (Hauser, H. and Wagner W., eds), pp. 453-482, Walter de Gruyter
43. WHO study group (1987) Acceptability of cell substrates for production of biologicals. World Health Organization Technical Report Series 747, 1-29
44. Berthold, W. et al. (1992) Experimental approaches to guarantee minimal risk of potential virus in purified monoclonal antibodies. Cytotechnology 9, 189-201
45. Brown, F. et al. (1999) A universal virus inactivant for decontaminating blood and biopharmaceutical products. Dev. Biol. Stand. 99, 119-130
46. Josic, D. et al. (1994) Purification of factor VIII and von Willebrand factor from human plasma by anion-exchange chromatography. J. Chromatogr. B Biomed. Appl. 662, 181-190
47. Brady, D. et al. (1990) Purification of monoclonal antibodies for human clinical use: validation of DNA and retroviral clearance. In: Separations For Biotechnology 2, SCI, Elsevier Applied Science, London-New York
48. Walter, J.K. et al. (1992) Virus removal and inactivation - concept and data for process validation of downstream processing. Biotech Forum Europe 9, 560-564
49. Werz, W. et al. (1997) Strategies to avoid virus transmissions by biopharmaceutic products. Arch. Virol. Suppl. 13, 245-256
50. Edy, V.G. (1989) Good Manufacturing Practice in the production of biologicals by cell cultures. NATO ASI Ser. E 156, 147-156